Long-term clinical outcome of phase IIb clinical trial of percutaneous injection with holmium-166/chitosan complex (Milican) for the treatment of small hepatocellular carcinoma
Long-term clinical outcome of phase IIb clinical trial of percutaneous injection with holmium-166/chitosan complex (Milican) for the treatment of small hepatocellular carcinoma
复制标题
DOI：
10.1158/1078-0432.ccr-05-1730
复制
发表时间：
2006-01-15
影响因子：
11.5
通讯作者：
Moon, YM
中科院分区：
文献类型：
--
作者：
Kim, JK;Han, KH;Moon, YM
目的：本研究的目的是评估IIb期临床研究后的长期肿瘤反应以及经皮钬166（Ho-166）/壳聚糖复合物注射（PHI）治疗小肝细胞癌作为局部消融治疗的安全性。 166 Ho 是一种源自天然钬 165 的放射性同位素。我们开发了一种 Ho-166/壳聚糖复合物（Milican，Dong Wha Pharmaceutical Co，首尔，韩国），使用壳聚糖作为载体，将放射性物质保留在肿瘤内。实验设计：40 名单发性肝细胞癌患者
Purpose: The purpose of this study was to evaluate the long-term tumor response after phase IIb clinical study and the safety of percutaneous holmium-166 (Ho-166)/chitosan complex injection (PHI) therapy for small hepatocellular carcinoma as a local ablative treatment. 166 Ho is a radioactive isotope derived from natural holmium-165. We developed a Ho-166/chitosan complex (Milican, Dong Wha Pharmaceutical Co., Seoul, Korea) using chitosan as a vehicle to retain the radioactive material within the tumor.Experimental Design: Forty patients with single hepatocellular carcinoma